Loading stock data…
DMRA
$20.96+0.05 (+0.24%)
After Hours$20.96+0.00 (+0.00%)· Last close Jun 9
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Damora Therapeutics, Inc. in the Healthcare sector is trading at $20.96. Wall Street consensus targets $43.14 (7 analysts), implying a +105.8% move over the next 12 months. The stock is currently 45% below its 52-week high of $38.33, remaining 5.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +105.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$20.96
Potential Downside
0%
Whystock Fair Value$20.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$43.14+105.8%
Range$35.00 – $51.00
Fundamentals
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that target...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-45.95%
Volume
Today's trading volume
459,938
Recent News
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
Damora Therapeutics recently overhauled its leadership team, appointing Jennifer Jarrett as President and CEO and naming Brian Burkavage as principal financial and accounting officer following the planned departure of CFO Lori Firmani effective May 1, 2026. The combination of Jarrett’s oncology and investment banking background with a new finance lead points to a sharpened focus on advancing DMR-001 and preparing for future commercialization. Next, we examine how this leadership reshaping,...
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive […]
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum
CFO transition puts Damora Therapeutics (DMRA) in focus Damora Therapeutics (NasdaqCM:DMRA) is back on investors’ radar after the company announced that Lori Firmani has stepped down as Chief Financial Officer. Brian Burkavage has taken over the role. See our latest analysis for Damora Therapeutics. The CFO transition comes after a period of strong momentum, with a year to date share price return of 18.84% and a 1 year total shareholder return of around 7x, even though the 3 and 5 year total...
Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says
Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin target